Business
Agenus Corporate Update and Second Quarter 2021 Financial Report
$200M received from BMS for anti-TIGIT bispecific antibody collaborationFDA cleared IND for AGEN1777 clinical enrollmentAGEN1181 rapidly advancing in the
About this update from Agenus Inc.
[{"type":"text","content":"$200M received from BMS for anti-TIGIT bispecific antibody collaborationFDA cleared IND for AGEN1777 clinical enrollmentAGEN1181 rapidly advancing in the clinic; data to be presented in 2H 2021Cell therapy subsidiary MiNK Therapeutics filed confidential S-1 for planned IPOFDA accepted balstilimab BLA for Priority Review with December PDUFA date LEXINGTON, Mass., Aug. 09, 2021 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today provided a corporate update and reported financial results for the second quarter of 2021. “In the first half of this year, we announced a collaboration with BMS and advanced our flagship clinical candidate AGEN1181 to an important data inflection point,” said Garo Armen, PhD, Chairman and Chief Executive Officer of Agenus. “In the second half, we will disclose this data at a key cancer conference and be ready with our commercial platform in preparation for a balstilimab launch.” AGEN1181 (Fc-enhanced anti-CTLA-4): Clinical data support superior activity in difficult-to-treat cancers Updated clinical data for AGEN1181 alone and in combination with balstilimab will be presented at an upcoming conference.Clinical responses seen in patients refractory to approved immunotherapies, including patients with microsatellite stable (MSS) tumors and melanoma, endometrial, and ovarian cancer with the low-affinity FcyRIIIA allele. No immune mediated hypophysitis, pneumonitis, or hepatitis (typically seen with first generation anti-CTLA-4s) were reported.Registrational trials targeted to commence by year-end 2021 with a focus on rapid path to Biologics License Application (BLA) submission. MiNK Therapeutics: Allogeneic iNKT cell therapy company advances towards IPO MiNK Therapeutics (currently an Agenus company) filed a confidential S-1 to support a planned Initial Public Offering (IPO).Phase 1 trial of AGENT-797 in hematologic cancers dose cohorts completed with data readouts planned in the second half of 2021; Phase 1/2 expansion trials in viral acute respiratory distress syndrome (ARDS) are underway. AGEN1777 (Fc-enhanced anti-TIGIT bispecific): Collaboration with BMS provides additional cash resources to advance Agenus’ high value dr...